Status:
Ready to upload
Record number:
2118
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
Most recent risk assessment for Lung Cancer (Council of Europe, 2018): Any form of newly diagnosed lung cancer represents an Unacceptable Risk for organ donation. Treated lung cancer is considered to be High Risk, but this may be modified by curative therapy and recurrence-free time with increasing probability of cure. (Note: This recommendation covers lung cancers including high grade neuroendocrine lung tumors, e.g. small cell carcinoma).
Time to detection:
Approximately 10 months
Alerting signals, symptoms, evidence of occurrence:
Dyspnea on exertion and shoulder pain led to CT scan showing lung mass
Demonstration of imputability or root cause:
Donor origin identified by PCR assay
Imputability grade:
3 Definite/Certain/Proven
Groups audience:
Keywords:
References:
Suggest new keywords:
Malignancy
Case Report
Deceased donor
Lung transplant
DNA typing
Molecular analysis
Lung cancer, small cell
Therapy discussed
Reference attachment:
Suggest references:
Darbinyan K et al. Cancer diagnosis after solid organ transplantation: do we need to know the cell of origin?
Note:
First review MN 4/15/22; second review CLFF 06-May-2022 (absolutely agree, independent read of article, equivalent comments)
Expert comments for publication:
This is a report of donor origin small cell lung carcinoma that is directed toward the oncology community. The report focuses on the pros and cons of various methods of determining host versus donor cell of origin of tumors in the transplant patient (XY chromosome FISH, PCR assays, generation sequencing and HLA typing). It is also briefly mentioned that the patient was treated with a carboplatin etoposide regimen and was well at time of the report, several months later (approx. 11-12 months). Exact time frames are not given.